Background: Congenital hyperinsulinism (CHI) is hallmarked by persistent hypoketotic hypoglycemia in infancy. In the majority of all patients, CHI is caused by mutations in the KATP channel genes ABCC8 and KCNJ11, but other genes in the insulin-regulatory pathway have also been described. Repeated episodes of hypoglycemia include an increased risk of seizures and intellectual disability. So far, controlled psychometric studies on cognitive, motor, speech, and social-emotional outcome of CHI patients are missing. Until now, neurodevelopmental long-term outcome in CHI patients has only been measured by questionnaires, self-, parental-, or caregiver-administered instruments. Methods: This is a prospective study of 60 patients (median age 3.3 years, range 3 months to 57 years): 48 with a diffuse, 9 with a focal, and 3 with an atypical histology. Neurodevelopmental outcome was assessed using standardized psychological tests and questionnaires. Results: 28 of 60 patients showed developmental delay (46.7%). 9 of 57 patients had cognitive deficits (15.8%), 7 of 26 patients had speech problems (26.9%), and 17 of 44 patients had motor problems (38.6%). In 5 of 53 patients, social-emotional problems were reported. Outcome and the underlying genetic defect were not correlated. Conclusions: Motor problems seem to be prominent in CHI patients. Despite a high incidence of developmental delay, a permanent cognitive defect was only detectable in 9 of 58 patients.

Keywords:
Congenital hyperinsulinism, Clinical trial, Cognitive development, Children and adolescents, Hypoglycemia
1.
Koh TH, Aynsley-Green A, Tarbit M, Eyre JA: Neural dysfunction during hypoglycaemia. Arch Dis Child 1988; 63: 1353–1358.
2.
Sempoux C, Guiot Y, Jaubert F, Rahier J: Focal and diffuse forms of congenital hyperinsulinism: the keys for differential diagnosis. Endocr Pathol 2004; 15: 241–246.
3.
Henquin JC, Sempoux C, Marchandise J, Godecharles S, Guiot Y, Nenquin M, Rahier J: Congenital hyperinsulinism caused by hexokinase I expression or glucokinase-activating mutation in a subset of beta-cells. Diabetes 2013; 62: 1689–1696.
4.
Izumi T, Takeshige H, Arai T, Sugama M, Mizushima M, Fukuyama Y, Mabuchi G: Prospective study of nesidioblastosis in newborns and infants: hypoglycemic seizures, epileptogenesis and the significance of the C-peptide suppression test in pancreatectomy. Acta Paediatr Jpn 1997; 39: 10–17.
5.
Menni F, de Lonlay P, Sevin C, Touati G, Peigne C, Barbier V, Nihoul-Fekete C, Saudubray JM, Robert JJ: Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia. Pediatrics 2001; 107: 476–479.
6.
De Leon DD, Stanley CA: Mechanisms of disease: advances in diagnosis and treatment of hyperinsulinism in neonates. Nat Clin Pract Endocrinol Metab 2007; 3: 57–68.
7.
Mazor-Aronovitch K, Gillis D, Lobel D, Hirsch HJ, Pinhas-Hamiel O, Modan-Moses D, Glaser B, Landau H: Long-term neurodevelopmental outcome in conservatively treated congenital hyperinsulinism. Eur J Endocrinol 2007; 157: 491–497.
8.
Lord K, Dzata E, Snider KE, Gallagher PR, De Leon DD: Clinical presentation and management of children with diffuse and focal hyperinsulinism: a review of 223 cases. J Clin Endocrinol Metab 2013; 98:E1786–E1789.
9.
Lord K, Radcliffe J, Gallagher PR, Adzick NS, Stanley CA, De Leon DD: High risk of diabetes and neurobehavioral deficits in individuals with surgically treated hyperinsulinism. J Clin Endocrinol Metab 2015; 100: 4133–4139.
10.
Meissner T, Wendel U, Burgard P, Schaetzle S, Mayatepek E: Long-term follow-up of 114 patients with congenital hyperinsulinism. Eur J Endocrinol 2003; 149: 43–51.
11.
Avatapalle HB, Banerjee I, Shah S, et al: Abnormal neurodevelopmental outcomes are common in children with transient congenital hyperinsulinism. Front Endocrinol (Lausanne) 2013; 4: 60.
12.
Amaral AI: Effects of hypoglycaemia on neuronal metabolism in the adult brain: role of alternative substrates to glucose. J Inherit Metab Dis 2013; 36: 621–634.
13.
Haces ML, Montiel T, Massieu L: Selective vulnerability of brain regions to oxidative stress in a non-coma model of insulin-induced hypoglycemia. Neuroscience 2010; 165: 28–38.
14.
Banerjee I, Avatapalle B, Padidela R, Stevens A, Cosgrove KE, Clayton PE, Dunne MJ: Integrating genetic and imaging investigations into the clinical management of congenital hyperinsulinism. Clin Endocrinol (Oxf) 2013; 78: 803–813.
15.
Otonkoski T, Nanto-Salonen K, Seppanen M, et al: Noninvasive diagnosis of focal hyperinsulinism of infancy with [F-18]-DOPA positron emission tomography. Diabetes 2006; 55: 13–18.
16.
Thornton PS, Stanley CA, De Leon DD, et al: Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. J Pediatr 2015; 167: 238–245.
17.
Arnoux JB, de Lonlay P, Ribeiro MJ, et al: Congenital hyperinsulinism. Early Hum Dev 2010; 86: 287–294.
18.
Barthlen W, Varol E, Empting S, Wieland I, Zenker M, Mohnike W, Vogelgesang S, Mohnike K: Surgery in focal congenital hyperinsulinism (CHI) – The “Hyperinsulinism Germany International” experience in 30 children. Pediatr Endocrinol Rev 2016; 14: 129–137.
19.
Gloyn AL, Siddiqui J, Ellard S: Mutations in the genes encoding the pancreatic beta-cell K-ATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat 2006; 27: 220–231.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.